Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly pill could help shed pounds in obesity trial

NCT ID NCT07281937

Disease control Sponsor: Verdiva Bio Dev Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 18, 2026 · Updated 4 times

Summary

This phase 2b trial tests a weekly oral tablet called ecnoglutide (VRB-101) for weight loss in 206 adults with obesity or overweight plus weight-related health problems. Participants receive either the drug or a placebo for several weeks. The main goal is to see how much body weight they lose on average.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ecnoglutide (VRB-101), a weekly oral tablet
What this could lead to
If successful, this could provide a convenient weekly pill for significant weight loss in people with obesity or overweight and related health issues.
What could go wrong
This is a mid-stage trial with only 206 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

206 people

The number who actually took part.

Started

Nov 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have hemoglobin A1c (HbA1c) \<6.5%. * Have a BMI of ≥30 kg/m2 OR ≥27 kg/m2 and \<30 kg/m2 with at least 1 weight-related comorbidity. * Have a self-reported history of stable body weight for the 3 months prior to randomization (≤5% body weight change). * Participants of childbearing potential must be non-pregnant and non-lactating and must agree to use study-specified contraceptive methods. Exclusion Criteria: * Have any prior diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or other forms of diabetes mellitus. A participant with a history of gestational diabetes may be included in the study if the participant has an HbA1c \< 6.5% at Screening. * Have at least 1 laboratory value suggestive of diabetes during Screening, including 1 or more of HbA1c ≥6.5% (48 mmol/mol) or random glucose ≥200 mg/dL (11.1 mmol/L). * Have had exposure to glucagon-like peptide -1 (GLP-1) 6 months prior to Screening or any prior history of known or suspected hypersensitivity/allergies, intolerability, or lack of efficacy to these medications. Have known or suspected hypersensitivity to study intervention(s), to selective GLP-1 receptor agonist (RA) or glucose-dependent insulinotropic peptide (GIP)/GLP-1 or GLP-1/glucagon (GCG) dual receptor agonists. * Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time within the dosing period, including follow -up, and for at least 60 days after the last dose of study intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Clinical Study Site 101

    Rochester, New York, 14609, United States

  • Clinical Study Site 102

    San Antonio, Texas, 78229, United States

  • Clinical Study Site 103

    Anniston, Alabama, 36207, United States

  • Clinical Study Site 104

    San Antonio, Texas, 78240, United States

  • Clinical Study Site 105

    Norman, Oklahoma, 73069, United States

  • Clinical Study Site 106

    Wichita, Kansas, 67207, United States

  • Clinical Study Site 107

    Montclair, California, 91763, United States

  • Clinical Study Site 108

    Monroe, North Carolina, 28112, United States

  • Clinical Study Site 109

    Cullman, Alabama, 35055, United States

  • Clinical Study Site 110

    Phoenix, Arizona, 85028, United States

  • Clinical Study Site 111

    Anaheim, California, 92801, United States

  • Clinical Study Site 112

    Dallas, Texas, 75251, United States

  • Clinical Study Site 113

    Little Rock, Arkansas, 72205, United States

  • Clinical Study Site 114

    Duncansville, Pennsylvania, 16635, United States

  • Clinical Study Site 115

    Knoxville, Tennessee, 37909, United States

  • Clinical Study Site 116

    West Des Moines, Iowa, 50266, United States

  • Clinical Study Site 117

    Binghamton, New York, 13905, United States

  • Clinical Study Site 118

    Tarzana, California, 91356, United States

  • Clinical Study Site 119

    Decatur, Georgia, 30030, United States

  • Clinical Study Site 120

    Charlotte, North Carolina, 28210, United States

  • Clinical Study Site 121

    Omaha, Nebraska, 68134, United States

  • Clinical Study Site 122

    Southfield, Michigan, 48076, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.